Diabetes, Vol 42, Issue 5 696-705, Copyright © 1993 by American Diabetes Association

ARTICLES

Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes

H Kuzuya, N Matsuura, M Sakamoto, H Makino, Y Sakamoto, T Kadowaki, Y Suzuki, M Kobayashi, Y Akazawa, M Nomura and al. et
Second Department of Internal Medicine, Kyoto University School of Medicine, Japan.

Extreme insulin resistance occurs in patients with primary defects in insulin action at the receptor or postreceptor levels. The condition commonly is associated with acanthosis nigricans and ovarian masculinization. Despite a marked increase in insulin secretion, some patients develop frank diabetes mellitus that does not respond adequately to insulin therapy. Insulinlike growth factor I exerts metabolic effects similar to those of insulin. This study assessed the potential effectiveness of IGF-I as a blood glucose lowering agent in patients with extreme insulin resistance syndromes, including type A insulin resistance, congenital generalized lipodystrophy, and leprechaunism. Among the 11 patients studied, some exhibited mutated insulin receptors, whereas others were suspected to have defects in postreceptor sites. In each patient, plasma glucose levels decreased in response to subcutaneous injections of recombinant human IGF-I (0.1-0.3 mg/kg body wt). The degree of the decrease was roughly comparable with that observed in normal individuals. IGF-I also reduced plasma insulin concentrations. A long-term trial of IGF-I (up to 16 mo) showed that IGF-I (0.1-0.4 mg/kg body wt twice daily) is effective in lowering both fasting and postprandial plasma glucose concentrations with decreases in both fructosamine and HbA1c values. Improvement of acanthosis nigricans was observed in some of the patients. These results suggest that recombinant human IGF-I could be used clinically as a hypoglycemic agent in diabetic patients with extreme insulin resistance in whom insulin treatment is ineffective.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. McDonald, R. M Williams, F. M Regan, R. K Semple, and D. B Dunger IGF-I treatment of insulin resistance Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S51 - S56. [Abstract] [Full Text] [PDF]

				Y. Hattori, H. Satoh, T. Namatame, S. Hattori, and K. Kasai A Patient With Extreme Insulin Resistance Syndrome Treated With Pioglitazone Diabetes Care, October 1, 2006; 29(10): 2328 - 2329. [Full Text] [PDF]

				S. Yakar, J.-L. Liu, A. M. Fernandez, Y. Wu, A. V. Schally, J. Frystyk, S. D. Chernausek, W. Mejia, and D. Le Roith Liver-Specific igf-1 Gene Deletion Leads to Muscle Insulin Insensitivity Diabetes, May 1, 2001; 50(5): 1110 - 1118. [Abstract] [Full Text]

				K. Cusi and R. DeFronzo Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3077 - 3084. [Abstract] [Full Text]

				D. R. Clemmons, A. C. Moses, M. J. McKay, A. Sommer, D. M. Rosen, and J. Ruckle The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence for in VivoBiological Activity J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1518 - 1524. [Abstract] [Full Text]

				L. E. Levitt Katz, R. J. Ferry Jr., C. A. Stanley, P. F. Collett-Solberg, L. Baker, and P. Cohen Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective {beta}-Cell Sulfonylurea Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3117 - 3124. [Abstract] [Full Text]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				L. J. Dominguez, M. Barbagallo, J. R. Sowers, and L. M. Resnick Magnesium Responsiveness to Insulin and Insulin-Like Growth Factor I in Erythrocytes from Normotensive and Hypertensive Subjects J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4402 - 4407. [Abstract] [Full Text]

				S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner Insulin-Like Growth Factor-I Resistance Endocr. Rev., October 1, 1998; 19(5): 625 - 646. [Abstract] [Full Text]

				A. Sandra, M. Boes, B. L. Dake, J. B. Stokes, and R. S. Bar Infused IGF-I/IGFBP-3 complex causes glomerular localization of IGF-I in the rat kidney Am J Physiol Endocrinol Metab, July 1, 1998; 275(1): E32 - E37. [Abstract] [Full Text] [PDF]

				R. M KNOTT Insulin-like growth factor type 1---friend or foe? Br. J. Ophthalmol., July 1, 1998; 82(7): 719 - 720. [Full Text]

				J. Nakae, M. Kato, M. Murashita, N. Shinohara, T. Tajima, and K. Fujieda Long-Term Effect of Recombinant Human Insulin-Like Growth Factor I on Metabolic and Growth Control in a Patient with Leprechaunism J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 542 - 549. [Abstract] [Full Text]

				K. Thrailkill, T. Quattrin, L. Baker, J. Litton, K. Dwigun, M. Rearson, M. Poppenheimer, D. Kotlovker, D. Giltinan, N. Gesundheit, et al. Dual Hormonal Replacement Therapy with Insulin and Recombinant Human Insulin-Like Growth Factor (IGF)-I in Insulin-Dependent Diabetes Mellitus: Effects on the Growth Hormone/IGF/IGF-Binding Protein System J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1181 - 1187. [Abstract] [Full Text] [PDF]

				D. Le Roith Insulin-Like Growth Factors N. Engl. J. Med., February 27, 1997; 336(9): 633 - 640. [Full Text] [PDF]

				Y. Takahashi, K. Tobe, H. Kadowaki, D. Katsumata, Y. Fukushima, Y. Yazaki, Y. Akanuma, and T. Kadowaki Roles of Insulin Receptor Substrate-1 and Shc on Insulin-Like Growth Factor I Receptor Signaling in Early Passages of Cultured Human Fibroblasts Endocrinology, February 1, 1997; 138(2): 741 - 750. [Abstract] [Full Text] [PDF]